Zoetis (ZTS) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Zoetis Inc. is a company that focuses on creating and selling animal health medicines, vaccines, and diagnostic products globally. They work with a range of animals, including livestock like cattle, swine, poultry, fish, sheep, dogs, cats, and horses. Their products cover parasiticides, vaccines, dermatology, pharmaceuticals, anti-infectives, diagnostics, and feed additives.

Moreover, Zoetis offers a variety of animal health diagnostic services, including point-of-care products, diagnostic instruments, rapid tests, reference kits, blood glucose monitors, as well as non-pharmaceutical items such as nutritionals, biodevices, genetic tests, and precision animal health services. They distribute their products to veterinarians, livestock farmers, and pet owners.

Established in 1952, Zoetis Inc. is headquartered in Parsippany, New Jersey. They have collaborated with Blacksmith Medicines, Inc. to develop new antibiotics specifically for animal health. For more information, you can visit their website at https://www.zoetis.com.

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Zoetis (ZTS) - Stock Price & Dividends

ZTS Stock Overview

Market Cap in USD 90,296m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2013-02-01

ZTS Stock Ratings

Fundamental 8.33
Dividend 7.68
Growth 5y 6.00
Rel. Performance vs Sector 0.32
Analysts 4.26
Fair Price Total Ret. 195.51
Fair Price DCF 97.04

ZTS Dividends

Yield 12m 0.78%
Yield on Cost 5y 1.68%
Dividends CAGR 5y 17.99%
Payout Consistency 100.0%

ZTS Growth Ratios

Growth 12m 20.40%
Growth Correlation 12m 45%
Growth Correlation 3m 17%
CAGR 5y 16.60%
CAGR / Mean Drawdown 1.13
Sharpe Ratio 12m 0.61
Alpha vs SP500 12m -10.01
Beta vs SP500 5y weekly 1.01
CAPM 8.02%
Average Daily Range 2m 1.98%
Regime Oscillator 81.77
Volatility GJR Garch 1y 35.98%
Price / SMA 50 3.5%
Price / SMA 200 11.2%
Current Volume 1997.5k
Average Volume 20d 2338.1k

External Links for ZTS Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ZTS stocks?
As of February 29, 2024, the stock is trading at USD 199.94 with a total of 1,997,533 shares traded.
Over the past week, the price has changed by +6.14%, over one month by +3.72%, over three months by +13.24% and over the past year by +21.92%.
Why is ZTS stock down?
Check with which Index or Commodity ZTS has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return ZTS Return S&P 500
1 Month 3.72% 3.05%
3 Months 13.24% 11.73%
12 Months 21.92% 29.22%
What is the forecast for ZTS stock price target?
According to ValueRays Forecast Model, ZTS Zoetis will be worth about 217.1 in February 2025. The stock is currently trading at 199.94. This means that the stock has a potential upside of +8.56%.
Issuer Forecast Upside
Wallstreet Target Price 225.9 13.0%
Analysts Target Price 222.8 11.4%
ValueRay Target Price 217.1 8.6%

The History and Evolution of Zoetis Inc

Zoetis Inc, recognized under the ticker ZTS on the New York Stock Exchange, marks its roots back to a division of Pfizer, the global pharmaceutical giant. Officially spun off from Pfizer in 2013, Zoetis quickly positioned itself as a leading force in the animal health industry. The company's journey from a segment of a larger entity to a standalone powerhouse illustrates its resilience and capability to innovate.

Core Business Insights

Zoetis Inc is predominantly known for its focus on animal health products and services. The company specializes in developing, manufacturing, and marketing a comprehensive range of medicines and vaccines for pets and livestock. Its core business revolves around four main categories: Companion Animal Products, Livestock Products, Diagnostics, and Genetics. The emphasis on innovation allows Zoetis to maintain a strong presence in both established and emerging markets, catering to a broad spectrum of animal health needs.

Exploring the Side Businesses

Beyond its primary focus, Zoetis also explores side businesses that complement its main operations. This includes investments in precision animal farming technology and collaborations aimed at environmental sustainability within the sector. Through such endeavors, Zoetis not only broadens its impact but also ensures a holistic approach to animal health and welfare.

Current Market Status

As of the current market conditions, Zoetis continues to exhibit strong performance and growth potential. The company's strategic initiatives, such as expanding its product portfolio and geographical presence, have solidified its status as a leader in the animal health sector. Furthermore, Zoetis's commitment to research and development positions it well to navigate future challenges and opportunities. The consistent pursuit of excellence and a customer-centric approach underpins Zoetis's market resilience and outlook for sustained success.